Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women of African American background; self identified~* Patients with stage 2 hypertension defined as MSSBP ≥ 160 mmHg and \< 200 mmHg at Visit 5 (randomization~Exclusion Criteria:~* Office blood pressure measured by cuff (MSDBP ≥ 110 mmHg and/or MSSBP ≥ 200 mmHg)~* Patients on 4 or more antihypertensive medications.~* Patients with uncontrolled hypertension (MSSBP \>180 mmHg) taking more than 1 antihypertensive medication at Visit 1~* Refractory hypertension, defined as, unresponsive to triple drug therapy at the maximum dose of each drug, one of which must be a diuretic, and not at blood pressure goal (140/90 mmHg). Therapy with a fixed dose combination of two active substances represent two drugs.~* History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.~* Evidence of a secondary form of hypertension, including but not limited to any of the following:~  * coarctation of the aorta~ * hyperaldosteronism~ * unilateral or bilateral renal artery stenosis~ * Cushing's disease~ * polycystic kidney disease~ * pheochromocytoma~* Known Keith-Wagener grade III or IV hypertensive retinopathy.~* History of angioedema due to usage of an ARB or ACE inhibitor.~* History of hypertensive encephalopathy, cerebrovascular accident, transient ischemic attack, heart failure (NYHA Class II-IV), coronary bypass graft surgery (CABG), percutaneous coronary intervention (PCI), unstable angina pectoris, or myocardial infarction in the last 12 months~Other protocol defined inclusion/exclusion criteria applied

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aliskiren/Amlodipine (Type: EXPERIMENTAL): Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
- Amlodipine (Type: ACTIVE_COMPARATOR): Amlodipine 5mg titrated to 10 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).